Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated
neuropathy typically characterised by symmetrical involvement, and proximal as well as …

Since the first clinical trials conducted after World War II, chemotherapeutic drugs have been
extensively used in the clinic as the main cancer treatment either alone or as an adjuvant …

To revise the 2010 consensus guideline on chronic inflammatory demyelinating
polyradiculoneuropathy (CIDP). Seventeen disease experts, a patient representative, and …

Background and purpose A fraction of patients with antibody‐mediated autoimmune
diseases remain unresponsive to first‐/second‐line and sometimes even to escalation …

Bortezomib is a first-in-class, potent, selective and reversible proteasome inhibitor approved
for the treatment of multiple myeloma (MM) and relapsed/refractory mantle cell lymphoma. In …

Organ-specific autoimmunity is often characterized by autoantibodies targeting proteins
expressed in the affected tissue. A subgroup of autoimmunopathies has recently emerged …

Autoimmune diseases (ADs) are conditions in which the immune system cannot distinguish
self from non-self and, as a result, tissue injury occurs primarily due to the action of various …

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common
chronic inflammatory neuropathy. CIDP is diagnosed according to the European Federation …

Vincristine and bortezomib are effective chemotherapeutics widely used to treat
hematological cancers. Vincristine blocks tubulin polymerization, whereas bortezomib is a …

Inflammatory neuropathies with pathogenic involvement of the nodes of Ranvier through
autoantibodies have been increasingly characterized in the past years. The so‐called anti …